Expression of the high-risk human papillomavirus (HPV) E6 and E7 oncogenes is essential for the initiationHigh-risk human papillomavirus (hrHPV)-positive cervical cancer cells harbor integrated HPV genomic DNA and are uniquely dependent upon the expression of two viral oncogenes, E6 and E7, for the maintenance of the transformed phenotype (40). hrHPV E6 is best known for its ability to target p53 for proteasomal degradation via its association with the E6-associated protein (E6-AP), a ubiquitin ligase (52,53,64). Additionally, hrHPV E6 activates telomerase to extend the life span of primary human keratinocytes (28,33,58) and binds to and deregulates several PDZ proteins that are known to regulate cell polarity, adhesion, and proliferation (27,32,41,57). This results in deregulation of tumor-suppressive activity and, in so doing, contributes to carcinogenesis. hrHPV E7 binds to and degrades members of the retinoblastoma (Rb) family, resulting in the transcription of E2F target genes such as cyclin E and cyclin A which are responsible for S-phase progression (11, 37). Additional E7 activities include the inhibition of the cyclin-dependent kinase inhibitors p21 CIP1 and p27 KIP1 which activate Rb (22, 24). Together, both hrHPV E6 and E7 contribute to carcinogenesis by suppressing apoptosis and senescence and by stimulating cellular proliferation. Consequently, a number of reports have pioneered various approaches to inhibit E6 and E7 function in HPV-positive cancer cells for the specific induction of cellular growth arrest and death (1,18,48,54). This includes the use of oncogene-specific peptide aptamers (3, 43), antisense technology (59), RNA interference (RNAi) (4,30,45), and the expression of viral E2 protein (7,39,44,56,63). Furthermore, in vivo experiments have provided proof of concept for the therapeutic targeting of E6/E7 in HPV-driven tumors in the presence and absence of conventional treatments (18,25,60).Several laboratories, including ours, have previously described the consequences of virally delivered E2 expression in HPV-positive cervical cancer cells: E6/E7 transcription ceased, followed by the reactivation of Rb and p53 tumor suppressors, cell cycle arrest, and eventually the induction of a synchronized cellular senescence phenotype. This was observed following the expression of bovine papillomavirus type 1 (BPV1) E2 transactivator (E2-TA), but not the transcriptional repressor (E2-TR), in HPV-positive cancer cells (10,17). Similar phenotypes were observed using a temperature-sensitive BPV1 E2 (E2ts) protein that is functional at the permissive temperature of 32°C but not at 37°C and above (8,62). Senescence induction in cervical cancer cells was identified by the typical flat-cell morphology (34), upregulation of senescence markers including senescence-associated -galactosidase (SA--Gal) activity (9), and a transcriptional profile that is reminiscent of replicatively senescent primary cells (23). Rescue of E2-expressing HeLa cells from either E6 or E7 repression further revealed that senescence...